Dr. Paul Nghiem

For the Media

Dr. Paul Nghiem

Dr. Paul Nghiem is a cancer biologist with an interest in signal transduction, cell cycle checkpoints, and immunology.  He is one of the world's foremost experts on a rare, deadly and difficulty-to-treat skin cancer called Merkel cell carcinoma (MCC).  His reserach has identified genetic mutations that may drive MCC and shed light on how a specific virus may trigger tumor development.

Resources for more information

Overview of Paul Nghiem's Clinical/Research Focus
Dr. Nghiem is discovering new ways to prevent and treat skin cancers by studying the systems that control cell division. These systems help prevent cells with damaged DNA from reproducing and, when they malfunction, can affect cells’ chances of becoming cancerous.

Paul Nghiem - Short Bio

Paul Nghiem Laboratory
Dr. Nghiem laboratory is focused on the biology of skin cancer, managing several clinical studies of its genetic mechanisms and optimal clinical management of patients.  He has a particular interest is Merkel cell carcinoma, an aggressive, virus-driven skin cancer for which the immune system plays a particularly important role in controlling.


Hutch Team

For more information or to arrange an interview, please contact Fred Hutch at (206) 667-2210 or email our media relations team.



Download photos and views a video of Dr. Paul Nghiem.

Related Stories

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.